Publications by authors named "Saleta Fernandez Barbeira"
Article Synopsis
- - The study examined gender differences in ischemia-reperfusion times in patients with ST-segment elevation acute myocardial infarction (STEMI) over a long-term period at a tertiary hospital.
- - A total of 2,668 patients were analyzed, revealing that women experienced longer delays in seeking medical help and receiving treatment compared to men, with median times of 220 minutes for women versus 197 minutes for men.
- - The findings highlight the critical need for increased awareness among women regarding heart disease symptoms, as delays in treatment can lead to higher rates of adverse cardiovascular events.
Impact of Comorbidities and Antiplatelet Regimen on Platelet Reactivity Levels in Patients Undergoing Transcatheter Aortic Valve Implantation.
J Cardiovasc Pharmacol
September 2021
The aim of our study is to assess the impact of anemia, chronic kidney disease, and diabetes mellitus on platelet reactivity (PR) in patients with severe aortic stenosis, both at baseline and after transcatheter aortic valve implantation (TAVI). This study is a prespecified subanalysis of the REAC-TAVI prospective, multicenter trial that included patients pretreated with aspirin + clopidogrel before TAVI. PR was measured at baseline and at 5 different time points after TAVI with the VerifyNow assay (Accriva Diagnostics, San Diego, CA), over a 3-month follow-up period.
View Article and Find Full Text PDFObjectives: Ticagrelor has proven more effective than clopidogrel at attaining a maintained suppression of high platelet reactivity (HPR) in aortic stenosis patients undergoing transcatheter aortic valve implantation (TAVI). This study aims to assess the influence of implanted valve type on the degree of platelet reactivity (PR) after TAVI.
Methods: This study is a prespecified analysis of REAC-TAVI, a prospective, multicenter study that included patients on dual-antiplatelet therapy with aspirin and clopidogrel before TAVI.
Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers in Acute Coronary Syndrome and Preserved Ventricular Ejection Fraction.
Angiology
November 2020
Article Synopsis
- ACE inhibitors (ACEi) and angiotensin II receptor blockers (ARB) show similar survival rates in heart failure patients with low ejection fraction, but their effectiveness in those with preserved ejection fraction post-acute coronary syndrome (ACS) is unclear.
- A study of 3,006 patients with preserved LVEF (≥40%) after an ACS found no significant differences in outcome measures like mortality and heart failure when comparing ACEi and ARB treatments over an average follow-up of 3.6 years.
- The results suggest that there is no prognostic advantage of using ACEi over ARB or vice versa in this patient population, highlighting the need for further studies to validate these findings.
Renin-Angiotensin System Blockade and Risk of Heart Failure After Myocardial Infarction Based on Left Ventricular Ejection Fraction: A Retrospective Cohort Study.
Am J Cardiovasc Drugs
October 2019
Article Synopsis
- This study aimed to explore how angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) impact the occurrence of heart failure (HF) following an acute myocardial infarction (AMI), considering patients' left ventricular ejection fraction (LVEF).
- Researchers analyzed data from 8,169 AMI patients discharged from two Spanish hospitals between 2010 and 2016, employing various statistical methods to assess the relationship between ACEI/ARB use and heart failure admissions.
- Findings indicated that while ACEIs/ARBs showed no significant benefit for patients with LVEF over 40%, they significantly reduced HF admissions in patients with LVEF 40% or lower, suggesting
Objectives: The REAC-TAVI (Assessment of platelet REACtivity after Transcatheter Aortic Valve Implantation) trial enrolled patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) pre-treated with aspirin + clopidogrel, aimed to compare the efficacy of clopidogrel and ticagrelor in suppressing high platelet reactivity (HPR) after TAVI.
Background: Current recommendations support short-term use of aspirin + clopidogrel for patients with severe AS undergoing TAVR despite the lack of compelling evidence.
Methods: This was a prospective, randomized, multicenter investigation.
Introduction And Objectives: There is little evidence on rates of stent thrombosis (ST) in patients receiving dual antiplatelet therapy (DAPT) with ticagrelor or prasugrel. The aim of this study was to analyze the incidence and predictors of ST after an acute coronary syndrome among patients receiving DAPT with ticagrelor vs prasugrel.
Methods: We used data from the RENAMI registry (REgistry of New Antiplatelet therapy in patients with acute Myocardial Infarction), analyzing a total of 4123 acute coronary syndrome patients discharged with DAPT with ticagrelor or prasugrel in 11 centers in 6 European countries.
A 73-year-old man was admitted for non-ST segment elevation acute myocardial infarction. Coronary angiography suggested intrastent thrombosis as the etiology, but optical coherence tomography revealed a non-expanded stent, which was successfuly crushed and covered with a new stent.
View Article and Find Full Text PDFAn 81-year-old woman was referred for primary angioplasty due to a myocardial infarction. Upon her arrival, the patient was in cardiogenic shock. Coronarography revealed a large filling defect within the left main coronary artery.
View Article and Find Full Text PDF